Stem Cell Pharmaceuticals, Inc.
Records under this name other than patents Stem Cell Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Stem Cell Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,486,122 | Methods of increasing body weight in a subject by administering TGF-&agr; Formerly held Lapsed on the fee record Ended Nov 26, 2014 · USPTO record | Lapsed on the fee record | Ended Nov 26, 2014 | USPTO record |
| US 6,815,418 | TGF-&agr; polypeptides, functional fragments and methods of use therefor Formerly held Lapsed on the fee record Ended Nov 9, 2012 · USPTO record | Lapsed on the fee record | Ended Nov 9, 2012 | USPTO record |
| US 6,764,683 | Loop peptide and TGF&agr; for stimulating stem cell proliferation and migration Lapsed on the fee record Ended Jul 20, 2012 · USPTO record | Lapsed on the fee record | Ended Jul 20, 2012 | USPTO record |
| US 7,329,645 | TGF-α polypeptides, functional fragments and methods of use therefor Formerly held Lapsed on the fee record Ended Feb 12, 2012 · USPTO record | Lapsed on the fee record | Ended Feb 12, 2012 | USPTO record |
| US 6,677,307 | TGF-&agr; polypeptides, functional fragments and methods of use therefor Formerly held Lapsed on the fee record Ended Jan 13, 2012 · USPTO record | Lapsed on the fee record | Ended Jan 13, 2012 | USPTO record |
| US 4,863,899 | Biologically active polypeptides Formerly held Term ended Term ended no later than Sep 5, 2009 · Low confidence | Term ended | Term ended no later than Sep 5, 2009 | Low confidence |
| US 5,240,912 | Transforming growth factor (TGF) peptides Formerly held Term ended Term ended no later than Aug 31, 2013 · Low confidence | Term ended | Term ended no later than Aug 31, 2013 | Low confidence |